Other languages Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Real-time Estimate Cboe BZX Other stock markets 09:30:55 2024-05-15 am EDT			5-day change	1st Jan Change
7.93 ^USD	+0.63%		-3.08%	+73.19%

May. 09	Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14
Sector Update: Health Care Stocks Gain Premarket Tuesday	Mar. 12
Larimar Therapeutics Doses 1st Patient in Study of Movement Disorder Treatment	Mar. 11
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia	Mar. 11
Top Midday Gainers	Feb. 14
Larimar Therapeutics Starts Public Offering of Common Shares, Pre-Funded Warrants	Feb. 14
Top Midday Gainers	Feb. 13
Larimar Therapeutics Says Potential Friedreich's Ataxia Drug Well-Tolerated in Phase 2 Study	Feb. 12
Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia	Feb. 12
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors	23-10-03
Larimar Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Larimar Therapeutics Gets FDA Clearance to Proceed With Trials; Shares Rise	23-07-25
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial	23-07-25
Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes	23-07-17
Larimar Therapeutics Poised to Join Russell 3000 Index	23-06-22
Larimar Therapeutics Phase 2 Dose Exploration Study Shows CTI-1601 'Generally Well Tolerated' in Friedreich's Ataxia Trial	23-05-15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Other languages

Filters